ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.12
+1.36 (+3.05%)
As of 2:03PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close44.76
Open44.50
Bid45.75 x 100
Ask45.95 x 100
Day's Range44.35 - 46.90
52 Week Range41.06 - 91.75
Volume1,321,133
Avg. Volume764,626
Market Cap1.707B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-7.13
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est85.59
Trade prices are not sourced from all markets
  • Spark Therapeutics CEO on the future of gene therapy
    CNBC Videos2 days ago

    Spark Therapeutics CEO on the future of gene therapy

    Spark Therapeutics CEO Jeff Marrazzo speaks to CNBC's Meg Tirrell about the biotech company's hemophilia treatments and the potential for gene therapies.

  • Spark Therapeutics' gene therapy program brings stock dow...
    CNBC Videos2 days ago

    Spark Therapeutics' gene therapy program brings stock dow...

    CNBC's Meg Tirrell reports on the winners and losers in biotech from the ASH Conference.

  • Biotech winners and losers: ASH Hematology Conference
    CNBC Videos2 days ago

    Biotech winners and losers: ASH Hematology Conference

    CNBC's Meg Tirrell reports on the biotech and pharma headlines out of the ASH Hematology Conference.

  • Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs
    Zacks6 hours ago

    Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs

    The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.

  • Why This Biotech Stock Is Defying A Hematology-Related Pitfall
    Investor's Business Daily21 hours ago

    Why This Biotech Stock Is Defying A Hematology-Related Pitfall

    GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer drug data.

  • 3 Reasons Spark Therapeutics Is a Buy After Its Crash
    Motley Fool23 hours ago

    3 Reasons Spark Therapeutics Is a Buy After Its Crash

    A drubbing in its share price following data from a competitor could provide investors with a good buying opportunity.

  • Benzinga23 hours ago

    UBS Loses Conviction In Spark Therapeutics, Downgrades

    Spark Therapeutics Inc (NASDAQ: ONCE ) released  phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. The Analyst UBS' Carter Gould downgraded ...

  • Barrons.comyesterday

    Spark Therapeutics: This Looks Bad

    Shares of  Spark Therapeutics’ (ONCE)  are down on Tuesday, continuing their decline from Monday, when it reported disappointing data that lagged rival BioMarin(BRMN). Leerink's Joseph Schwartz and Dae ...

  • Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
    Zacksyesterday

    Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

    Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

  • Stocks May Bring Volatility for the Holidays
    InvestorPlaceyesterday

    Stocks May Bring Volatility for the Holidays

    U.S. equities mostly finished higher on Monday amid growing excitement over the rise of Bitcoin futures trading and the tendency for prices to rise this time of year — the Santa Rally and all that. In the end, the Dow Jones Industrial Average gained 0.2%, the S&P 500 gained 0.2%, the Nasdaq Composite gained 0.5% and the Russell 2000 lost 0.1% continuing a recent string of underperformance. Treasury bonds were unchanged, the dollar was little change, gold lost 0.1% and crude oil gained 1.1%.

  • Barrons.com2 days ago

    Why Biotech Stocks Are Just Too Darn Scary! Spark Tumbles 35%

    Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. Case in point: Shares of Spark Therapeutics’ (ONCE) closed down 35% on Monday, after presenting disappointing data at the American Society of Hematology's (ASH) annual meeting. Spark's data on its hemophilia A gene therapy, while showing a reduction in bleeding, showed smaller increases in levels of factor VIII--the clotting protein that patients with hemophilia are missing--than were seen by rival BioMarin (BRMN).

  • What Happened in the Stock Market Today
    Motley Fool2 days ago

    What Happened in the Stock Market Today

    On a record day on Wall Street, two gene therapy specialists were making news.

  • Associated Press2 days ago

    Apple and Chesapeake Energy rise; Spark Therapeutics sinks

    Stocks that moved substantially or traded heavily Monday: Bluebird Bio Inc., up $30.65 to $201.80 Bluebird and Celgene reported positive results from an early clinical trial of a multiple myeloma treatment. ...

  • American City Business Journals2 days ago

    Why Spark Therapeutics stock price dropped by 40% this morning

    Spark Therapeutics’ stock price plunged more than 40 percent Monday morning after the Philadelphia-based gene therapy company provided an update of its experimental hemophilia A treatment. Preliminary clinical data showed the gene therapy treatments produced significant reductions in bleeding rates, but yielded much lower increases in levels of factor VIII — the clotting protein missing in hemophilia A patients. California-based BioMarin Pharmaceutical released study results on Saturday of its hemophilia A gene therapy candidate which fared better in raising factor VIII levels.

  • MarketWatch2 days ago

    Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting

    Biotech stocks were active Monday as analysts weighed in on a raft of announcements from companies attending the American Society of Hematology annual meeting.

  • SmarterAnalyst2 days ago

    Spark Therapeutics Inc (ONCE) Tanks as Hemophilia A Drug Disappoints in Trial; J.P. Morgan Shares Two Cents

    Spark Therapeutics Inc (NASDAQ:ONCE) tanked over 35% today after data from a Phase 1/2 study showed that patients suffering from hemophilia A may not benefit from the company's gene therapy. Spark presented additional Hemophilia A data on four patients treated with SPK-8011 at doses of 5E11vg/kg and 1E12vg/kg. Unfortunately, there was no difference in Factor VIII levels between patients given the low 5E11 dose, and the mid 1E12 dose. J.P. Morgan Cory Kasimov commented, "Though admittedly early, we were quite underwhelmed by the results from ONCE’s update for SPK-8011 in Hemophilia A presented this morning at ASH (significant variability and lack of consistency in factor expression levels).

  • Benzinga2 days ago

    Analyst: Weakness In Spark Therapeutics Is Overdone

    Spark Therapeutics Inc (NASDAQ: ONCE ) reported during the ASH conference an update concerning its SPK-8011 therapy, which has many investors concerned. The Analyst Cantor Fitzgerald's Elemer Piros maintains ...

  • Barrons.com2 days ago

    [$$] Spark Therapeutics Selloff Looks Overdone

    Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.

  • Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today
    Motley Fool2 days ago

    Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today

    The latest data for a candidate partnered with Pfizer bodes well for a potential competitor.

  • TheStreet.com2 days ago

    Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

    Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

  • MarketWatch2 days ago

    Spark Therapeutics shares slide more than 40% after hemophilia data disappoint

    Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive ...

  • Forbes2 days ago

    Five Winners -- And One Loser -- From Medicine's Big Meeting About Blood

    For the past two days, doctors who treat blood diseases have been meeting at the annual convention of the American Society of Hematology in Atlanta. There’s a lot of innovation coursing through this field. Here’s a guide to companies that are standing out.

  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 7. Index (PMI) data, output in the Healthcare sector is rising.

  • Forbes2 days ago

    Spark Shadows BioMarin In Hemophilia Gene Therapy Race

    Spark Therapeutics, the company likely to launch the first gene therapy in the U.S., is presenting data on both of its gene therapies for hemophilia this morning at the annual meeting of the American Society of Hematology in Atlanta.

  • GlobeNewswire2 days ago

    Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

    PHILADELPHIA, Dec. 11, 2017-- Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has dosed seven participants ...